The intracellular role of ATP has been recognized for many years; it is an energy source for many important reactions. Cellshavecomplexmechanismsfor synthesizing ATP and maintaining or rapidly restoring the intracellular level, and one might therefore expect that release of ATP to the extracellular milieu would rarely occur; teleological reasoning suggests that cells should guard their intracellular ATP at all costs, and the established view is that ATP does not cross the plasma membrane of viable cells -a suggestion that the selective release ofcytoplasmic ATP might be part of a physiological regulatory mechanism would, in the opinion of many, verge on the heretical.
Introduction
The intracellular role of ATP has been recognized for many years; it is an energy source for many important reactions. Cellshavecomplexmechanismsfor synthesizing ATP and maintaining or rapidly restoring the intracellular level, and one might therefore expect that release of ATP to the extracellular milieu would rarely occur; teleological reasoning suggests that cells should guard their intracellular ATP at all costs, and the established view is that ATP does not cross the plasma membrane of viable cells -a suggestion that the selective release ofcytoplasmic ATP might be part of a physiological regulatory mechanism would, in the opinion of many, verge on the heretical.
Nonetheless, extracellular ATP (and/or ADP) at low micromolar concentrations can influence many biological processes including platelet aggregation, vascular tone, neurotransmission (peripheral and central), cardiac function and muscle contraction. Nucleotides can be released from the cytoplasm of several cell types (and by exocytosis from platelets and neurones); they interact with specific receptors on the surface of many different cells and they aremetabolized locallybyectonucleotidases. The main purpose of this Review is to summarize current knowledge of these topics and to indulge in some modest speculation about the role ofextracellular ATP in biology and pathology.
Receptors recognizing ATP
Receptors can be classified on the basis of ligand binding studies or by using a pharmacological approach; for nucleotide receptors the latter method has been mainly employed (i.e. measurement of responses induced by a selected series of agonists and antagonists). Such an analysis can be complicated by several factors: the relation between receptor occupation and the elicited response is complex; the activity of an agonist reflects both its affinity for the receptor and its efficacy; receptors may interact with each other to give positive or negative cooperativity; agonists (and antagonists) may induce a response by acting at more than one receptor. In addition, the local concentrations of agonists (near the receptor site) can be difficult to assess, especially where ectoenzymes that metabolize the agonist exist on the cells used for receptor characterization studies.
Despite these limitations, a pharmacological approach has been used successfully to characterize various receptors, and Burnstock (1978) was the first to propose the subclassification of 'purinergic' receptors as either P1 (recognizing adenosine) or P2 (recognizing ATP). His classification was based on four criteria: 1, the relative potencies ofATP, ADP, AMP and adenosine; 2, selective antagonism, especially ofadenosine effects by methylxanthines; 3, activation of adenylate cyclase by adenosine (but not by ATP); 4, stimulation of prostaglandin synthesis by ATP (but not by adenosine).
Much of Burnstock's work at that time was concerned with ATP and/or adenosine released from 'purinergic' nerves (Burnstock, 1972) and the term 'purinergic receptors' reflected this emphasis on the neuroeffector junction; as receptors for ATP and adenosine also exist on cells with no neural connections, the term 'purinoceptor' is now generally used. Thus, P2 purinoceptors (with which this review is mainly concerned) are more responsive to ATP and ADP than to AMP and adenosine, are not blocked by methylxanthines, do not in general act via adenylate cyclase and may be associated with stimulation of prostaglandin production.
It has become increasingly evident that expansion of this original classification is necessary. Two categories of P1 (i.e. adenosine) purinoceptors have been discussed for some time (see Burnstock & Buckley, 1985 , for review), on the basis of the different effects they produce -for example, some activate and others inhibit adenylate cyclase. It is therefore not surprising that different categories of P2 purinoceptors are also emerging. A subdivision of P2 purinoceptors is now required, following several recent discoveries; examples of relevant findings are given below, with a representative (though not comprehensive) reference list.
1. Substitution of a methylene bridge in the polyphosphate chain increases smooth muscle stimulant or contractile potency (Brown et al., 1979; Dahlen & Hedqvist, 1980; Fedan et al., 1982; Cusack & Hourani, 1984; Kennedy & Burnstock, 1985b) , but reduces potency on smooth muscles that are relaxed by ATP (Maguire & Satchell, 1979; Brown & Burnstock, 1981 ; Kennedy et al., 1985) .
2. Stereoselectivity with respect to either the ribose moiety, using L-ribose substituted analogues, or the modified phosphate groups in phosphorothioate analogues, can be very high (e.g. several thousand-fold) in some tissues but negligible in others Cusack & Planker, 1979; Cusack & Hourani, 1981; (Gough et al., 1973; Kennedy & Burnstock, 1985a; Martin et al., 1985) with little or no effect in others .
5. The receptor on platelets exhibits a positive response to ADP but not to ATP, which is antagonistic (see Haslam & Cusack, 1981 ; Cusack et al., 1985 , for reviews).
6. Receptors on lymphocytes that modulate cytotoxicity and DNA synthesis require 30-100 /M-ATP to induce a response, compared with 1 I,UM for most other cells and tissues. The receptor on mast cells, which apparently recognizes the tetrabasic form ATP4- (Cockcroft & Gomperts, 1979) , also requires -100 tM-ATP because ATP4-is only a small proportion of the total ATP added. Table 1 summarizes some of the evidence for different classes of P2 purinoceptors, from which four main categories emerge. I have proposed the designation T for the receptor present only on thrombocytes, platelets and megakaryocytes. The receptors on blood vessels, smooth muscle, heart, hepatocytes and parotid acinar cells are divided into subclasses X and Y, following the terminology proposed by , who collated the effects of several agonists on different smooth muscle preparations and identified two receptor subclasses responsible for contraction and relaxation. These three categories are all activated by < 1 UM of the most active agonists. The other major subclass that can be identified (designated Z for alphabetical consistency) is that on mast cells and lymphocytes, which requires 100 /LM-ATP for activation -though it has not been established whether lymphocytes, like mast cells, recognize ATP4-.
Not all observations are conveniently accommodated by this classification -for example, the guinea pig vas deferens showed unexpected stereoselectivity to the ribose enantiomers of ATP , or even within the smooth muscle itself (Kennedy & Burnstock, 1985a) . Furthermore, if a P1 receptor is also present ATP can interact with this after conversion to AMP or adenosine -or, in some tissues, apparently by direct action on it (Collis & Pettinger, 1982; Moody et al., 1984) .
The classification of P2 receptors is at present based almost entirely on the relative potencies of various agonists, which is unsatisfactory for several reasons, as Collis (1985) (Burgess et al., 1981; Hugues et al., 1982; Jenkinson et al., 1983) and ANAPP3, which selectively blocks the action of ATP in some tissues, is irreversible and light-sensitive (Hogaboom et al., 1980) .
The examples shown in The platelet response observed following stimulation by ADP is a rapid change in shape from biconvex disk to spiny sphere and then aggregation (Born, 1962 (Born, , 1970 . ADP also inhibits platelet adenylate cyclase; pharmacological evidence indicates that this action of ADP is mediated by the same receptor . The concentrations of ADP required to produce a halfmaximal effect on platelet responses range from 0.2 to 0.8 /tM (Mills & Roberts, 1967; Born, 1970; Haslam, 1973) .
The platelet P2 purinoceptor is unusual in having been the subject of successful ligand binding studies with agonists and antagonists (Macfarlane et al., 1983) . ATP is a competitive inhibitor (Ki -20 /tM) of ADP-induced platelet aggregation (Macfarlane & Mills, 1974) and of binding to the receptor. GDP and other nucleoside diphosphates are much less potent agonists than ADP, and GTP, UTP etc. are much less effective than ATP as antagonists (see Haslam & Cusack, 1981, for review) . Although the platelet receptor is unique in being activated by ADP rather than ATP, it exhibits some of the characteristics of the P2y receptor: analogues with L-ribose substitutions or a methylene bridge in the phosphate chain are less potent, whereas 2-chloro-ADP and 2-methylthio-ADP are more potent (see Cusack et al., 1985, for review) . Mast cell secretion ATP induces calcium-dependent histamine secretion from mast cells (Keller, 1966; Dahlquist & Diamant, 1974) . The agonist form is the tetrabasic acid ATP4- (Cockcroft & Gomperts, 1979) membrane permeability to intracellular metabolites (Cockcroft & Gomperts, 1980) , and among the cytoplasmic constituents released by high concentrations (> 100 /M) of extracellular ATP is ATP itself; this generates additional extracellular ATP (Trams et al., 1980) , making interpretation difficult. Membrane permeability A non-lethal 'permeabilizing' effect of high concentrations of ATP has also been studied using cultured cells (e.g. 3T6, SV40-3T3). The responses are not produced by other nucleotides, are greater in transformed than in normal cells and are increased if the intracellular concentration of ATP falls (Dicker et al., 1980) . Although Dicker et al. (1980) suggested that the permeabilization resulted from phosphorylation of a 44 kDa membrane protein involved in the formation of an ' aqueous pore' in the membrane (Rozengurt & Heppel, 1979) , this protein was subsequently identified as a mitochondrial enzyme (Weisman et al., 1984) .
However, many surface membrane proteins are phosphorylated by ATP under 'non-permeabilizing' conditions (e.g. with ATP concentrations < 1 UM) which introduces the possibility that receptors for ATP on the cell surface could include kinases. Protein kinases utilizing extracellular ATP have been described on several cell types, including macrophages (Remold-O'Donnell, 1978) , hepatocytes (Sommarin et al., 1981) , adipocytes (Kang et al., 1979) and Hela cells (Kubler et al., 1982) . Ecto-nucleoside diphosphate kinases exist on platelets (Guccione et al., 1971 ) and endothelial cells (Pearson et al., 1980) . Indeed, the platelet enzyme was proposed as the receptor for ADP, although this concept has not found universal support (see Haslam & Cusack, 1981 , for review). Which, if any, of the P2 receptors discussed previously may involve ecto-kinases remains to be determined.
The permeabilizing effect of ATP should be distinguished from its ability to induce a selective increase in K+ permeability, which is associated with activation of the P2y receptor by low concentrations ofATP. This effect has been noted in several cell types, including astrocytes (Trams, 1974) , parotid acinar cells (Gallacher, 1982) and endothelial cells (Gordon & Martin, 1983) . In their studies with isolated hepatocytes, Jenkinson and his colleagues found that ATP (> I,UM) stimulated K+ efflux from guinea pig and rabbit (but not rat) cells, through a Ca2+-dependent channel that is blocked by apamin (Burgess et al., 1979 (Burgess et al., , 1981 . Earlier experiments with liver slices had revealed similar responses to ATP, but -30-fold higher concentrations were required, apparently because of ATP hydrolysis at the surface of the slices. A similar apamin-sensitive channel is present on rat muscle cells (Hugues et al., 1982) but not on rat liver cells (Jenkinson et al., 1983 ).
Immunomodulation ATP ( 3 30/M) inhibits antibody-dependent cytotoxicity and the activity of human or rat natural killer lymphocytes (Schmidt et al., 1984) . Adenosine, and other nucleotides including APPNP, were inactive. The mechanism responsible is presumed to involve postrecognition metabolic events, because ATP did not inhibit the binding of natural killer cells to their targets.
ATP did not affect cell viability, protein synthesis, transmethylation in the cell membrane or permeability to deoxyuridine. Inhibition of macrophage-mediated cytotoxicity (either mouse or human), through an action on the effector cells by ATP (25-100 /tM) was observed by Cameron (1984) but not by Schmidt et al. (1984) .
Other effects of extracellular ATP ( 100 /M) on lymphocyte function have also been reported -it stimulates DNA synthesis in bone marrow and thymus cells, while inhibiting DNA synthesis in spleen, lymph node and peripheral blood lymphocytes (Gregory & Kern, 1978; Ikehara et al., 1981) . Stimulation of DNA synthesis by ATP was seen only with a subpopulation of precursor T-cells, containing high levels of terminal deoxynucleotidyl transferase. Cardiovascular effects Endothelium-dependent vasodilation. The hypotensive and vasodilator actions of nucleotides have been noted for many years (Drury & Szent Gyorgyi, 1929; Green & Stoner, 1950; Duff et al., 1954; Wolf & Berne, 1956 ). Indeed, Drury & Szent Gyorgyi can be credited with introducing the concept of a regulatory role for extracellular purines, although (as is evident from the references cited above) the topic attracted little interest for about 20 years. In common with some other vasodilators (e.g. acetylcholine), ATP has little or no relaxant effect in many conventional isolated arterial preparations; the reason for this discrepancy remained obscure until Furchgott and his colleagues discovered that such vasodilators required the presence of endothelium (Furchgott & Zawadzki, 1980) . This vasodilation is mediated by a substance known as endothelium-derived relaxing factor (EDRF), which is released from the endothelial cells by various stimuli including ATP (DeMey & Vanhoutte, 1981) . The structure of EDRF has not yet been established, but it is produced by endothelial cells in situ and in culture; it acts (like the nitrovasodilators) by stimulating guanylate cyclase in vascular smooth muscle cells and thus inducing their relaxation, its half-life is approx. 6 s in physiological buffer at 37°C, it is inactivated by binding to albumin and it contains a reactive oxygen (possibly carbonyl) group (Rapoport & Murad, 1983; Griffith et al., 1984; Furchgott et al., 1984) . Studies with a range of ATP analogues have established some of the characteristics of the P2y receptor on endothelial cells that mediates the release of EDRF (Martin et al., 1985) . Fig. 1 shows the equipotency ofATP and ADP, and the relative ineffectiveness of AMP and adenosine. There is considerable variation in the amount of endothelium-dependent vasodilation that can be induced at different vascular sites -some blood vessels (e.g. the rabbit ear artery) apparently do not have a P2Y
receptor on their endothelial cells (Kennedy & Burnstock, 1985b) .
Vasoconstriction. P2X receptors mediating vasoconstriction exist on the smooth muscle of some arteries (Chapal & Loubatieres-Mariani, 1983; Kennedy et al., 1985; . If the endothelial cells of the same artery have P2y receptors that mediate endothelium-derived vasodilation (as occurs in the rat femoral artery; Kennedy et al., 1985) , loss of endothelial cells (or their failure to generate EDRF or prostacyclin) could result in a vasoconstriction rather than vasodilation response to ATP and/or ADP. Such paradoxical vasospasm induced by other stimuli has been demonstrated in the coronary bed (Ku, 1982) . To complicate the Prostacyclin production. ATP can also induce the release of prostaglandins (including prostacyclin) from perfused vascular beds and isolated blood vessels (Needleman et al., 1974; Schwartzman et al., 1981; Boeynaems & Galand, 1983) , and from cultured endothelial cells of pig aorta, bovine aorta and human umbilical vein Van Coevorden & Boeynaems, 1984) . Responses to ATP and ADP are transient, basal production being restored within about 5 min (Fig. 2) proposed that adenosine, which is released from the working heart (especially under hypoxic conditions), is an endogenous regulator of coronary flow. It is not appropriate to deal with this topic here, but the interested reader can consult several reviews, for example those of Berne (1964 Berne ( , 1980 . ATP is rapidly converted to adenosine in the coronary bed (see under 'Metabolism') and therefore some of its effects may be the result of this conversion; however, ATP is more potent than adenosine as a coronary dilator (Burnstock, 1980) There are at least three sites through which ATP could exert effects on coronary flow and cardiac function: coronary smooth muscle cells, endothelial cells and cardiac myocytes. ATP has little effect on the endotheliumdenuded rabbit coronary artery, although the intact artery is dilated by ATP (Griffith et al., 1984) . This suggests that the major site of action is on the endothelial cells. EDRF and/or prostacyclin could be responsible for the observed vasodilation, but since the doses of ATP required to stimulate prostacyclin production by the perfused heart are greater than those that induce coronary vasodilation, it would appear that the effects are mainly due to EDRF production. The effects of ATP on cardiac function are, in general, depressant -decreased heart rate, force of atrial contraction and (to a lesser extent) force ofventricular contraction also. These effects seem to be due mainly to adenosine formation, although P2 as well as P1 receptors have been found in the hearts of various animal species, including amphibians (Burnstock & Meghji, 1981; .
Non-vascular smooth muscle
The potent biological actions of purines on smooth muscle of the gastrointestinal tract and other locations have been recognized for many years, and evidence has accumulated indicating that ATP is involved in the physiological regulation of non-vascular smooth muscle tone through liberation from 'purinergic' nerve endings (see Burnstock, 1972, for review) . ATP effects on the gut are usually inhibitory, and it can modulate reflexes that facilitate the movement of material along the alimentary Vol. 233 canal (e.g. by opening sphincters). The minimal effective concentration of ATP is around 0.1 /tM. Purinergic control is indicated at several regions of the gastrointestinal tract, including the oesophagus, stomach, small and large intestine and internal anal sphincter. Although most of the gastrointestinal responses mediated by purinoceptors are inhibitory, excitatory responses, possibly under purinergic control, are also found in the small intestine of several vertebrate species (see, for example, Furness & Costa, 1973) .
There is evidence for purinergic control of smooth muscle in lung, trachea, uterus, bladder, seminal vesicles and eye in several species including mammals, amphibians, reptiles, birds and fish (see Burnstock, 1975) . ATP may also be involved in smooth muscle function of invertebrates (e.g. crustacea, molluscs, starfish, snail and even coelenterates), as indicated by the effects of exogenous ATP and the presence of nerve profiles with the appearance of purinergic terminals (Campbell & Burnstock, 1968 ). This suggests that purinergic systems may be an early evolutionary development. References to recent work on purinergic regulation of non-vascular smooth muscle and the effects ofATP can be found under 'Receptors ' and 'Neuromodulation'. Neuromodulation ATP can exert effects at neuroeffector junctions by acting directly as a neurotransmitter, by increasing or decreasing the release of other neurotransmitters, or by modulating their action. ATP is ubiquitously present in neural tissue, and it is released during nerve stimulation of many tissues including the rabbit ear artery (Holton, 1959) , the guinea pig taenia coli (Rutherford & Burnstock, 1978) and vas deferens (Westfall et al., 1978) and the electric organ of Torpedo (Israel et al., 1976) .
The concept of ATP as a transmitter in 'purinergic' nerves (Burnstock, 1971 ) derived from observations indicating that a component of the autonomic nervous system, neither adrenergic nor cholinergic, was associated with smooth muscle in parts of the gastrointestinal tract and elsewhere, including the central nervous system. Evidence for ATP as a neurotransmitter included: measurements of ATP release afer nerve stimulation; effects ofnerve stimulation mimicked by exogenous ATP; presence at neuroeffector junctions of enzymes that metabolized ATP; 'purinergic' nerve endings exhibiting large, opaque characteristic vesicles that contained ATP. ATP is released from some nerves as a co-transmitter -for example, with noradrenaline (Sneddon & Burnstock, 1984a, b; Burnstock & Sneddon, 1985) . Potter et al. (1983) , who cultured single neurones from cervical ganglion, found some that secreted a purinergic transmitterinadditiontoacetylcholineandnoradrenaline; when co-cultured with cardiac myocytes, the main effect exerted by some of these neurones was purinergic. ATP can modulate membrane potentials in autonomic ganglia by depolarizing the membrane through a decrease in the resting K+ conductance (Henon & McAfee, 1983; Akasu et al., 1983; Silinsky & Ginsborg, 1983) .
Purinergic effects in the central nervous system are, in general, inhibitory: depression of the firing rate of central neurones, and reducing transmitter release from cholinergic and adrenergic synapses (in peripheral and in central neurones). Some neurones in the central nervous system (for example, in the cerebral cortex ofrats) showed biphasic responses to ATP -primary excitation followed by depression -although most show only a reduction in firing rate to ATP (Stone & Taylor, 1978) . Other studies have revealed nerves excited by ATP in the sensory regions of the brain and in the outer layer of the dorsal horn of the spinal cord (Jahr & Jessell, 1983; Salt & Hill, 1983; Fyffe & Perl, 1984) . Some clinical observations have implicated adenine nucleotides in schizophrenia and in depression (Burnstock, 1980) . Shock Studies on the role of ATP in shock were stimulated initially by the experiments of Dyckerhoff & Schoercher (1939) who investigated the systemic toxicity of muscle extracts and those of Bielschowsky & Green (1943) who established that the 'myotoxin' responsible was ATP or its immediate hydrolytic products. This was followed by the work of Kalckar & Lowry (1947) which established a causal link between ATP and traumatic shock, and the studies of Green et al. (1949) , who found that the plasma 'adenylate' content of over 100 battle casualties averaged around 70 /LM with some values over 200 /tM. They stressed that these values almost certainly underestimated the peak concentrations, and we now know that any extracellular ATP in the circulation is metabolized rapidly, mainly by ectoenzymes on the endothelial cells (q.v.). Mellanby commented in the foreword to the classic monograph by Green & Stoner (1950) that ATP has ' extracellular actions of great potency' and that 'nucleotides are definitely released from cells into the general body fluids when the circulation returns to previously ischaemic tissue'. The results of Trams et al. (1980) suggest that when sufficient ATP (> 50/M) is released into the plasma the process becomes selfperpetuating, because the extracellular ATP makes erythrocytes semi-permeable so that they release more ATP from their cytoplasm, and the ectoenzymes that normally catabolize nucleotides in plasma are no longer able to cope.
There are at least two components to the role of ATP in circulatory shock. First, the cardiovascular effects when ATP appears in the plasma (see above); the generalized vasodilation induced by ATP is associated with a profound decrease in systolic blood pressure and progressive anoxia. Secondly, the consequences of a reduced level of cytoplasmic ATP in the cells from which the ATP appearing in the plasma was released.
In other studies on ATP and, circulatory shock an apparent paradox emerged: the administration of ATP is, in some circumstances, beneficial. Chaudry and his colleagues studied the ischaemia associated with circulatory collapse induced by shock or by vessel ligation (in liver and kidney) and found that infusion of ATP-MgCl2 complex produced a sustained improvement in tissue ATP levels, mitochondrial and cellular functions and in tissue ultrastructure and blood flow (Chaudry et al., 1974; Ohkawa et al., 1984) . The mechanisms responsible for these effects are not clear: microcirculation is improved, but not apparently through vasodilation (Ohkawa et al., 1983) .
Whatever the cellular mechanisms, the ability of exogenous ATP to ameliorate the consequences of shock probably involves normalizing intracellular nucleotide metabolism, whereas the shock-inducing effects of ATP released into the plasma result mainly from overstimulation of cardiovascular P2 receptors -which may thus be rendered temporarily refractory to ATP, allowing the ATP subsequently administered to exert its beneficial effects.
Sources
The effects of ATP discussed above can be seen in proper perspective only in relation to the sources from which such ATP might arise. ATP is a ubiquitous intracellular constituent and therefore any cell could potentially serve as a source of extracellular ATP. In practice, it is convenient to consider three categories: 1, purinergic nerve terminals and associated cells; 2, cells in or adjacent to the circulating blood; 3, other cells. We should also keep in mind the following questions. What stimuli induce release? What is the mechanism of release? What concentrations of ATP can be achieved extracellularly?
When ATP was measured in the perfusate of the rabbit ear artery after nerve stimulation (Holton, 1959) , it was not clear whether the source was nerves or the effector cells such as smooth muscle. It now appears that ATP can be released from both such sources; e.g., about one-third of the ATP released from the superfused taenia coli on transmural stimulation is neuronal in origin (Rutherford & Burnstock, 1978) , although the proportions may vary with the tissue used.
Release of purines from brain slices and synaptosomes has been measured in response to depolarizing stimuli (see Stone, 1981 , for review). Release of purines paralleled that ofthe transmitter y-aminobutyrate in cerebrocortical synaptosomal preparations, but a significant proportion of purine release from rat cerebral cortex was apparently somal or axonal (Lloyd & Stone, 1983) . In summary, ATP can be released from synaptic vesicles by degranulation, but nucleotides can also be released from other locations during nerve stimulation (see White, 1985 , for review). The concentrations of ATP generated extracellularly at synapses are difficult to estimate; the concentrations that can be measured in superfusing fluid probably bear little relation to those in the vicinity of the nerve terminal.
The 'dense granules' in blood platelets have been compared with the storage vesicles in some neurones, because these granules are packed with amines and nucleotides. Platelets contain -40 nmol of ATP and ADP per mg of protein (Da Prada et al., 1981) , and the plasma concentration of ATP following platelet activation by thrombin in vitro is 12 /tM (Ingerman et al., 1979) ; the concentration of (ATP + ADP) would be -20 4aM. Platelet degranulation in vivo usually takes place where platelets aggregate and thus their granule contents are released from platelets that are clustered together, not suspended uniformly throughout the blood. The rate of accumulation of platelets during the initial formation of a haemostatic plug is rapid (around 104/s; Born & Richardson, 1980) , and when these aggregated platelets degranulate the pericellular concentration of ATP and ADP will be very high: their concentration within the storage granules is I M. Degranulation may also occur when platelets interact, perhaps transiently, with the vascular wall (George, 1985) and this could result in a smaller, more localized release of nucleotides.
Another cell type that contains nucleotides in storage granules, discharges the contents by degranulation, and thus may contribute to the local release of ATP into the plasma, is the adrenal medulla. ATP represents about 150 ofthe dry weight ofadrenal granules (Hillarp, 1959) , and its release accompanies that of the catecholamines (Smith, 1968) .
It is important to emphasize at this point that although degranulation (i.e. exocytosis) is the process by which nucleotides are released from platelets, neurones and cells of the adrenal medulla, most other cells (which contain ATP in their cytoplasm and mitochondria, but not in storage granules) must release nucleotides by a different mechanism. ATPcanbe released from vascularendothelial cells and smooth muscle cells in culture (Pearson & Gordon, 1979) ; the cells remained viable, and the release was selective inasmuch as no lactate dehydrogenase was detectable extracellularly, but there was no evidence that the released nucleotides had been compartmentalized within the cell. The ATP was apparently released from the cytoplasm, not from mitochondria. The mechanisms involved have not yet been identified: effective stimuli include neutral proteinases such as trypsin and thrombin, which require an active catalytic site ofthe enzyme (Lollar & Owen, 1981) , and cationic proteins or polymers (LeRoy et al., 1984) . The release process may involve a change in the topography of plasma membrane constituents, resulting in the opening of a pore that allows selective release of some low Mr cytoplasmic constituents. 'Budding' of surface membrane vesicles (presumably containing cytoplasmic nucleotides) occurs in some cells (Black, 1980; Dvorak et al., 1981; George et al., 1982) , and the subsequent lysis of these would produce extracellular nucleotides, but it seems unlikely that this process could be responsible for the rapid release of cytoplasmic ATP observed in the experiments cited above. Concentrations of the nucleotides sufficient to affect platelet aggregation were produced in these experiments; the relative amounts of extracellular ATP and ADP depended on their metabolism by ectonucleotidases (q.v.). Such release from vascular endothelial and/or smooth muscle cells in vivo is another potential source of ATP in plasma.
Extracellular ATP has been detected in the blood perfusing working muscle beds (Parkinson, 1973; Forrester, 1972; Forrester & Hassan, 1973; Forrester & Lind, 1969) , and in the plasma flowing through micropunctures of single blood vessels, or from a small incision made in human skin (Born & Kratzer, 1984) . There were two peaks of ATP release observed by Born & Kratzer (1984) : the first, which appeared only 2-4 s after the incision, reached 0.2-2 SM, and the authors suggested that the source of this ATP was cells of the vascular wall. The second peak (-20 /M, 3-5 min after the stimulus) was apparently a consequence of platelet degranulation, stimulated by exposed collagen in the vascular wall and by thrombin formed during clotting. ATP is also found in the solutions perfusing a working heart, especially if made hypoxic (Paddle & Burnstock, 1974; Clemens & Forrester, 1981) . Release is increased by sympathetic nerve stimulation (Fredholm et al., 1982) . Because these solutions were blood-free, the source of the ATP could not be blood cells, but it was not established whether the source was purinergic nerves, myocardium, smooth muscle cells or endothelial cells. ATP release has, however, been measured from isolated, hypoxic cardiomyocytes (Forrester & Williams, 1977) , in which the intracellular ATP remained approximately constant. Pentilla & Trump (1974) made similar observations with rat renal cortex and Ehrlich ascites cells.
The concentrations of extracellular ATP generated Vol. 233 locally in the circulation are not easy to determine. The micromolar concentrations measured by Born & Kratzer (1984) and in the perfusates of the working hearts and muscle beds underestimate the concentration at the sites of release, because of dilution and because of the efficient ectonucleotidases on vascular endothelial cells (see under 'Metabolism').
Cytoplasmic ATP in most cells is > 5 mm in concentration, and a significant proportion can be released with no loss of cell viability; thus, the concentrations of pericellular ATP could easily reach the high micromolar range. The local concentrations of ATP will depend on the amount released, the volume of distribution in the extracellular space, and the capacity (and accessibility) of catabolic enzymes, especially the ectonucleotidases on adjacent cells. Teleological reasoning suggests that this may be why the distribution of ectonucleotidases is widespread (Trams & Lauter, 1974) . Metabolism It has been known since 1950 that a bolus of ATP is virtually all removed by a single passage through the lung (Binet & Burstein, 1950) . The rate of removal of ATP is much greater than can be accounted for by enzymes in the blood; metabolism by lungs perfused with blood is, in fact, no greater than in blood-free perfused lung (Ryan & Smith, 1971) . Metabolism ofnucleotides in blood alone is relatively inefficient: the ti for ATP incubated in samples of cell-free plasma or whole blood at 37°C is around 30 min and 10 min respectively (Jorgensen, 1956; Trams et al., 1980) whereas the ti of nucleotides in the perfused lung is 0.2 s or less (Ryan &Smith, 1971 ). The efficiency of nucleotide metabolism in the lung is not a peculiarity of the pulmonary vasculature: nucleotides are also efficiently metabolized by the perfused heart (Williamson & Di Pietro, 1965; Baer& Drummond, 1968) , and 99% of a bolus of ATP can be removed on a single.
passage (Paddle & Burnstock, 1974) .
The enzymes responsible for removal of ATP from the extracellularspaceareectonucleotidasesontheendothelial cells; Ryan & Smith (1971) found that the mean transit time of ATP and its metabolites was indistinguishable from that of a vascular space marker (Blue Dextran or albumin) in the perfused rat lung, and no enzymic activity was secreted into the lumen of the vessels (i.e. detectable in the perfusate). Subsequent electron microscopic cytochemical studies revealed that 5'-nucleotidase activity on pulmonary endothelial cells was localized to the luminal surface of the plasma membrane and was present mainly on the caveolae (Smith & Ryan, 1973; Ryan, 1982) .
Although most of the earlier studies on ectonucleotidases used AMP or ATP as substrates, some studies used ADP, both in perfused organs (Crutchley et al., 1978) and in isolated vessels (Lieberman et al., 1977) . The catabolism of ADP removes a platelet-aggregating agent from the plasma and might therefore be important in controlling thrombogenesis (Cooper et al., 1979) . To explore the substrate specificity and kinetic characteristics of endothelial ectonucleotidases in more detail, several groups have used cells in culture, from a variety ofanimal species and vascular sites (Glasgow et al., 1978; Dosne et al., 1978; Crutchley et al., 1980; Pearson et al., 1980) . There are, apparently, three separate enzymes that sequentially catabolize ATP -+ ADP -* AMP -* adenosine (Fig. 3) , with Km values on cultured pig aortic endothelial ADP, and then sequentially to AMP and Ado, by the endothelial ecto-triphosphatase, -diphosphatase and 5'-nucleotidase respectively. Note the delay in formation of Ado, due to the inhibition of 5'-nucleotidase by ADP (see Slakey et al., 1985) . cells of around 500, 150 and 20 #mt respectively for ATP, ADP and AMP. The ecto-monophosphatase (5'-nucleotidase) is selectively inhibited by APCP (Pearson et al., 1980) , or by an antiserum to the purified enzyme (Stanley et al., 1980) , without affecting catabolism ofATP or ADP (J. L. Gordon, unpublished work). The ADPase is selectively inhibited by APPNP or APPCP, but no selective inhibitor of the ATPase has yet been found.
ADP is a poor inhibitor of the ATPase (Ki > 3 mM); when compared with the Km value ofADP as a substrate, this provides further evidence that the ADPase is distinct from the ATPase. Together with adenosine transport by endothelium, these ectonucleotidases provide a mechanism for regulating the concentrations of circulating vasoactive purines (Pearson & Gordon, 1985) .
Non-specific phosphatases do not contribute to nucleotide metabolism at the endothelial surface; metabolism of ATP, ADP or AMP is unaltered in the presence of a large excess of ,-glycerophosphate or p-nitrophenyl phosphate (Pearson et al., 1980) . The enzymes exhibit stereoselectivity with respect to the ribofuranosyl moiety and to the phosphate side chain: the nucleoside triphosphatase recognizes the A,fl,y-bidentate ATP-Mg complex and the diphosphatase similarly recognizes the A,a,fl-bidentate complex Pearson & Cusack, 1985) .
Ectonucleotidases are not restricted to endothelial cells, but have a widespread distribution amongst tissues and isolated cells such as blood platelets and leukocytes (see Pearson, 1985, for review) . The presence of ectonucleotidases on effector tissues such as skeletal, cardiac and smooth muscle, and within the central nervous system (Dunkley et al., 1966; Woo & Manery, 1975; Kreutzberg et al., 1978 Kreutzberg et al., , 1985 Moody et al., 1984) can complicate the interpretation ofexperiments involving purinergic nerve stimulation or exogenous nucleotides. Responses to nucleotides in several preparations depend on the susceptibility of the agonist to nucleotidases (Satchell & Burnstock, 1975; Brown et al., 1979; Moody et al., 1984; Cusack & Hourani, 1984; Hourani et al., 1985) . Furthermore, responses may be affected by the spatial distribution of receptors and nucleotidases on the cell surface, and by factors that regulate this. Membrane topography does not remain constant: transient domain segregation can occur (e.g. in response to stimuli) and this could result in regions rich in purinoceptors but not in ectoenzymes. Topography is altered by changes in membrane fluidity and interactions with the cytoskeleton (e.g. as a result of viral transformation, or different experimental conditions), which could therefore affect responses to stimuli; this may explain some of the discrepancies in the literature.
Conclusions
The history of research on extracellular ATP and related subjects falls into several stages. To the nearest decade, the important discoveries were as follows: purines are vasoactive (1930); ATP is vasoactive (1950); ATP is metabolized on passage through the lung and is released in shock (1950); ADP inducesplatelet aggregation and is released (with ATP) from platelet granules (1960); ATP is released at nerve terminals and affects smooth muscle tone (1970) 
